Loading clinical trials...
Loading clinical trials...
A Phase I Open-Label Dose Escalation Study Of Intravenous INKmune In Patients With Myelodysplastic Syndrome With Excess Blasts (MDS-EB-1/2 - MDS-CMML 1/2) Or Acute Myeloid Leukaemia (AML)
Conditions
Interventions
INKmune
Locations
3
Greece
Attikon University General Hospital
Athens, Attica, Greece
University Hospital Southampton NHS Foundation Trust
Southampton, Hampshire, United Kingdom
Sheffield Teaching Hospitals NHS FT - Royal Hallamshire Hospital
Sheffield, United Kingdom
Start Date
June 15, 2020
Primary Completion Date
March 28, 2024
Completion Date
April 26, 2024
Last Updated
July 18, 2024
NCT06345508
NCT05198830
NCT04235764
NCT05884320
NCT04550494
NCT06898450
Lead Sponsor
Inmune Bio, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions